IP Verse

Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The Same - EP2847223

The patent EP2847223 was granted to Trustees OF Dartmouth College on Apr 9, 2025. The application was originally filed on May 7, 2013 under application number EP13787935A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2847223

TRUSTEES OF DARTMOUTH COLLEGE
Application Number
EP13787935A
Filing Date
May 7, 2013
Status
Patent Maintained As Amended
Mar 7, 2025
Grant Date
Apr 9, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIMDec 20, 2019HOFFMANN EITLEADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004152105
DESCRIPTIONUS3832253
DESCRIPTIONUS3854480
DESCRIPTIONUS4452775
DESCRIPTIONUS4667014
DESCRIPTIONUS4748034
DESCRIPTIONUS5239660
DESCRIPTIONUS5929212
DESCRIPTIONWO0134768
DESCRIPTIONWO2008122039
DESCRIPTIONWO2011070443
INTERNATIONAL-SEARCH-REPORTUS2003119018
INTERNATIONAL-SEARCH-REPORTUS2004043401
INTERNATIONAL-SEARCH-REPORTUS2011027278
INTERNATIONAL-SEARCH-REPORTUS2011081346
INTERNATIONAL-SEARCH-REPORTUS2011217305
INTERNATIONAL-SEARCH-REPORTWO2011070443
OPPOSITIONUS2004152105
OPPOSITIONWO0134768
OPPOSITIONWO2009046407
OPPOSITIONWO2011070443
OPPOSITIONWO2012162067
OPPOSITIONWO2013169691
SEARCHUS2011081346
SEARCHWO0023573
SEARCHWO2006060878
SEARCHWO2009091826
SEARCHWO2011041093
SEARCHWO2011070443

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ARAKAWA et al., J. Biochem., (19960000), vol. 120, pages 657 - 62-
DESCRIPTION- BRANDT et al., J. Exp. Med., (20090000), vol. 206, pages 1495 - 1503-
DESCRIPTION- KOWOLIK et al., Cancer Res., (20060000), vol. 66, pages 10995 - 11004-
DESCRIPTION- MAHER et al., Nat. Biotechnol., (20020000), vol. 20, pages 70 - 75-
DESCRIPTION- MARCU-MALINA et al., Exp. Opin. Biol. Ther., (20090000), vol. 9, pages 579 - 91-
DESCRIPTION- PULE et al., Mol. Ther., (20050000), vol. 12, pages 933 - 941-
DESCRIPTION- WU et al., Nat. Biotechnol., (20050000), vol. 23, pages 1137 - 1146-
DESCRIPTION- ZHAO et al., J. Immunol., (20090000), vol. 183, pages 5563 - 5574-
DESCRIPTION- ZHONG et al., Mol. Ther., (20100000), vol. 18, pages 413 - 420-
DESCRIPTION- RAMOS et al., "Chimeric Antigen Receptor (CAR) - Engineered Lymphocytes for Cancer Therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:doi:10.1517/14712598.2011.573476, pages 855 - 873, XP055122639
INTERNATIONAL-SEARCH-REPORT- NAGORSEN ET AL., "Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab", EXPERIMENTAL CELL RESEARCH., (20110306), vol. 317, pages 1255 - 1260, XP028205663
OPPOSITION- BARGOU C. et al., "0598 PROLONGED LEUKEMIA FREE SURVIVAL FOLLOWING BLINATUMOMAB (ANTI-CD19 BITE® TREATMENT OF PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) OF B PRECURSOR ALL: UPDATED RESULTS OF A PHASE II STUDY", Haematologica. 15th Congress Annual Meeting of the European Hematology Association, (20100000), vol. 95, no. s2, page 250, XP055667910-
OPPOSITION- BARGOU R. et al., "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", Science, (20080815), vol. 321, no. 5891, pages 974 - 977, XP002572417-
OPPOSITION- KISCHEL et al., "Abstract #3252: Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110", 100th meeting of the American Association for Cancer Research (AACR), (20090418), XP055667919-
OPPOSITION- NAGORSEN et al., "Confirmation of Safety, Efficacy and Response Duration in NonHodgkin Lymphoma Patients Treated with 60μg/m2 /d of BiTE® Antibody Blinatumomab", Blood. ASH Annual Meeting Abstracts, (20090000), vol. 114, page 2723, XP055667894-
OPPOSITION- WU MING-RU et al., "NKp30-based chimeric antigen receptors promote T-cell effector functions and anti-tumor efficacy (53.11)", J Immunol, (20120000), vol. 188, no. 1 Suppl, page 53.11, XP055667878-
OPPOSITION- "Bispecific T Cell Engager for Cancer Therapy", BAEUERLE et al., Bispecific Antibodies, Berlin Heidelberg, Springer, (20110000), pages 273 - 287, XP055667883
OPPOSITION- NAGORSEN et al., "Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab", Exp Cell Res, (20110310), vol. 317, no. 9, pages 1255 - 1260, XP028205663
OPPOSITION- WOLF et al., "BiTEs: bispecific antibody constructs with unique anti-tumor activity", Drug Discovery Today, (20050915), vol. 10, no. 18, pages 1237 - 1244, XP005103829
OPPOSITION- LUTTERBUESE et al., "T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells", PNAS, (20100713), vol. 107, no. 28, pages 12605 - 12610, XP055067703
OPPOSITION- BRANDT et al., "The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans", J Exp Med, (20090615), vol. 206, no. 7, pages 1495 - 1503, XP009145615
OPPOSITION- CARTELLIERI et al., "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer", Journal of Biomedicine and Biotechnology, (20100100), vol. 2010, no. 956304, pages 1 - 13, XP002673541
OPPOSITION- SCHLERETH et al., "Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct", Cancer Res, (20050400), vol. 65, no. 7, pages 2882 - 2889, XP055363255
OPPOSITION- BAEUERLE et al., "Bispecific T-cell engaging antibodies for cancer therapy", Cancer Res, (20090609), vol. 69, no. 12, pages 4941 - 4944, XP002665118
OPPOSITION- BAEUERLE et al., "BiTE: a new class of antibodies that recruit T-cells", Drugs of the Future, (20080100), vol. 33, no. 2, pages 137 - 147, XP002667644
OPPOSITION- ZHANG et al., "An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo", J Immunol, (20120730), vol. 189, no. 5, pages 2290 - 2299, XP055066131
SEARCH- MARC CARTELLIERI ET AL, "Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, HINDAWI PUBLISHING CORPORATION, US, (20100101), vol. 2010, doi:10.1155/2010/956304, ISSN 1110-7243, pages 956304 - 1, XP002736525 [A] 1-15 * page 2, column r, paragraph 2 *
SEARCH- BAEUERLE PATRICK A ET AL, "Bispecific T-cell engaging antibodies for cancer therapy", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 69, no. 12, doi:10.1158/0008-5472.CAN-09-0547, ISSN 1538-7445, (20090615), pages 4941 - 4944, (20090609), XP002665118 [A] 1-15 * abstract * * page 4941, column r, paragraph 2 *
SEARCH- CARLOS A RAMOS ET AL, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 1471-2598, pages 855 - 873, XP055122639 [A] 1-15 * abstract * * page 11, paragraph 2 - paragraph 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents